Association between secondary mutations in human immunodeficiency virus type 1 protease and therapeutic outcome

被引：6
|
作者：
Frater, J
Dunn, D
Weber, JN
McClure, MO
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Div Med, Wright Fleming Inst, Jefferiss Res Labs, London W2 1PG, England
[2] MRC, HIV Clin Trials Unit, London, England
来源：
JOURNAL OF INFECTIOUS DISEASES | 2002年 / 185卷 / 09期
关键词：
D O I：
10.1086/340127
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1376 / 1376
页数：1
相关论文
共 50 条
  • [31] Regulation of intracellular human immunodeficiency virus type-1 protease activity
    Gatlin, J
    Arrigo, SJ
    Schmidt, MG
    VIROLOGY, 1998, 244 (01) : 87 - 96
  • [32] Enzymatic activity of human immunodeficiency virus type 1 protease in crowded solutions
    Ksenia Maximova
    Jakub Wojtczak
    Joanna Trylska
    European Biophysics Journal, 2019, 48 : 685 - 689
  • [33] Modular total chemical synthesis of a human immunodeficiency virus type 1 protease
    Johnson, Erik C. B.
    Malito, Enrico
    Shen, Yuequan
    Rich, Dan
    Tang, Wei-Jen
    Kent, Stephen B. H.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2007, 129 (37) : 11480 - 11490
  • [34] Comprehensive bioinformatic analysis of the specificity of human immunodeficiency virus type 1 protease
    You, LW
    Garwicz, D
    Rögnvaldsson, T
    JOURNAL OF VIROLOGY, 2005, 79 (19) : 12477 - 12486
  • [35] Enzymatic activity of human immunodeficiency virus type 1 protease in crowded solutions
    Maximova, Ksenia
    Wojtczak, Jakub
    Trylska, Joanna
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2019, 48 (07): : 685 - 689
  • [36] The Impact of Individual Human Immunodeficiency Virus Type 1 Protease Mutations on Drug Susceptibility Is Highly Influenced by Complex Interactions with the Background Protease Sequence
    Van Marck, H.
    Dierynck, I.
    Kraus, G.
    Hallenberger, S.
    Pattery, T.
    Muyldermans, G.
    Geeraert, L.
    Borozdina, L.
    Bonesteel, R.
    Aston, C.
    Shaw, E.
    Chen, Q.
    Martinez, C.
    Koka, V.
    Lee, J.
    Chi, E.
    de Bethune, M. -P.
    Hertogs, K.
    JOURNAL OF VIROLOGY, 2009, 83 (18) : 9512 - 9520
  • [37] Human immunodeficiency virus 1 protease inhibitors in clinical practice - Predictors of virological outcome
    Valdez, H
    Lederman, MM
    Woolley, I
    Walker, CJ
    Vernon, LT
    Hise, A
    Gripshover, BM
    ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (15) : 1771 - 1776
  • [38] Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1
    Loetsch, Joern
    Harder, Sebastian
    Stuermer, Martin
    Doerr, Hans-Wilhelm
    Geisslinger, Gerd
    Staszewski, Schlomo
    von Hentig, Nils
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (09) : 3264 - 3272
  • [39] PURIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF RECOMBINANT SIMIAN IMMUNODEFICIENCY VIRUS PROTEASE AND COMPARISON TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE
    GRANT, SK
    DECKMAN, IC
    MINNICH, MD
    CULP, J
    FRANKLIN, S
    DREYER, GB
    TOMASZEK, TA
    DEBOUCK, C
    MEEK, TD
    BIOCHEMISTRY, 1991, 30 (34) : 8424 - 8434
  • [40] Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication
    Kaplan, AH
    Manchester, M
    Smith, T
    Yang, YL
    Swanstrom, R
    JOURNAL OF VIROLOGY, 1996, 70 (09) : 5840 - 5844
12345